HK Stock Market Move | CMOC Group Limited (03993) rose nearly 4% in the afternoon, planning to spend $1 billion to acquire a gold mining project in Brazil. The annual gold production is expected to increase by about 8 tons.
Luoyang Molybdenum Industry (03993) rose nearly 4% in the afternoon, up 3.22% as of the time of publication, to 18.62 Hong Kong dollars, with a turnover of 421 million Hong Kong dollars.
CMOC Group Limited (03993) rose nearly 4% in the afternoon, up 3.22% to HK$18.62 as of the time of writing, with a trading volume of HK$4.21 billion.
On the news front, CMOC Group Limited recently announced the acquisition of 100% equity in three gold mine assets in Brazil owned by Canadian mining company Equinox Gold, with a total consideration of US$1.015 billion. These assets include the Aurizona gold mine, RDM gold mine, and Bahia Complex. The company is optimistic about the long-term market prospects for gold assets, and the purchase of Brazilian business assets is a major step in implementing the company's "dual-copper and gold" merger and acquisition strategy.
Galaxy Securities released a research report stating that this transaction is the company's second gold mine project in South America after the Caijiakou gold mine, which will have good synergies with the company's existing silver-phosphate assets in Brazil, further enhancing the company's gold asset portfolio. If this transaction is successfully completed, the company's gold production is expected to reach 8 tons annually; and with the Odin Mine in Ecuador in production, the company's gold production is expected to exceed 20 tons per year.
Related Articles

Hangzhou Anysoft Information Technology (300571.SZ) subsidiary signed a 38.25 million yuan computing power service contract.

Yahong Pharmaceutical (688176.SH): APL-2401 clinical trial application approved by the National Medical Products Administration.

Yabao Pharmaceutical Group (600351.SH): GLX002 has obtained the notice of approval for clinical trial of the drug.
Hangzhou Anysoft Information Technology (300571.SZ) subsidiary signed a 38.25 million yuan computing power service contract.

Yahong Pharmaceutical (688176.SH): APL-2401 clinical trial application approved by the National Medical Products Administration.

Yabao Pharmaceutical Group (600351.SH): GLX002 has obtained the notice of approval for clinical trial of the drug.

RECOMMEND

Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025

What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025

Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025


